INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 201 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2019. The put-call ratio across all filers is 1.09 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $5,509,000 | -49.2% | 87,500 | +0.0% | 0.20% | -28.6% |
| Q4 2019 | $10,839,000 | -2.7% | 87,468 | -47.9% | 0.28% | -8.9% |
| Q3 2019 | $11,142,000 | +8.3% | 167,902 | +29.8% | 0.30% | +19.3% |
| Q2 2019 | $10,292,000 | -17.9% | 129,346 | +15.4% | 0.25% | -19.1% |
| Q1 2019 | $12,538,000 | +15.7% | 112,087 | +4.2% | 0.31% | +2.6% |
| Q4 2018 | $10,840,000 | -14.2% | 107,553 | +7.6% | 0.31% | +2.3% |
| Q3 2018 | $12,628,000 | -0.6% | 99,938 | -34.0% | 0.30% | -5.7% |
| Q2 2018 | $12,707,000 | +79.2% | 151,434 | +31.4% | 0.32% | +83.2% |
| Q1 2018 | $7,090,000 | +0.5% | 115,245 | -4.6% | 0.17% | +4.2% |
| Q4 2017 | $7,055,000 | – | 120,757 | – | 0.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 234,375 | $23,623,000 | 22.67% |
| Boxer Capital, LLC | 600,000 | $60,474,000 | 7.47% |
| DLD Asset Management, LP | 834,600 | $84,136,000 | 5.77% |
| GREAT POINT PARTNERS LLC | 200,000 | $20,158,000 | 2.55% |
| BB BIOTECH AG | 575,719 | $58,027,000 | 1.86% |
| Elk Creek Partners, LLC | 207,657 | $20,930,000 | 1.74% |
| ALTRINSIC GLOBAL ADVISORS LLC | 277,944 | $28,014,000 | 1.34% |
| Sarissa Capital Management LP | 54,000 | $5,442,000 | 1.21% |
| QCM Cayman, Ltd. | 2,181 | $220,000 | 0.90% |
| Opus Point Partners Management, LLC | 3,534 | $356,000 | 0.78% |